Latest news with #MedTech
Yahoo
3 days ago
- Business
- Yahoo
Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US
Johnson & Johnson (NYSE:JNJ) is one of the 10 Best and Cheap Stocks to Buy Now. On June 19, Johnson & Johnson (NYSE:JNJ) announced the launch of two new plating systems in the United States under its VOLT platform, called Distal Radius and Proximal Humerus 3.5 Plating Systems. The systems are designed to treat the two most commonly fractured bones, which are the distal radius near the wrist and the proximal humerus near the shoulder. These injuries are common in people above 65 years old. Johnson & Johnson (NYSE:JNJ) designed these systems in collaboration with the Hand Expert Group from the AO Technical Commission. The new plate has a new shape that sits more distally on the bone fragments and has a less prominent profile to reduce soft tissue irritation, thereby improving the overall comfort and healing process. A smiling baby with an array of baby care products in the foreground. Johnson & Johnson (NYSE:JNJ) highlighted that the systems fill in a critical gap in the current treatment of fractures. The systems are now readily available across the United States. Johnson & Johnson (NYSE:JNJ) is an international global healthcare company. The company operates through two segments including innovative medicine and MedTech. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Globe and Mail
3 days ago
- Business
- Globe and Mail
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's Key Competitors in the Medical Devices Market J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report
Forbes
4 days ago
- Health
- Forbes
Medical Device Cybersecurity And The Not-So-Hidden Threat Of Backdoors
Founder, Blue Goat Cyber | MedTech Cybersecurity Leader | Speaker & Author | 24x Ironman | Securing Innovation & Patient Safety. The threats guiding the world of medical device cybersecurity encompass many attack types. Data breaches, malware and ransomware continue to increase, making the environment volatile and ever-changing. While the Food and Drug Administration (FDA) requires cybersecurity controls and protocols before and after approval, no device or network can be completely risk-free. In analyzing the threat landscape, calling attention to backdoors is important. Backdoors describe hidden functionality that's unknown to device users. They can lead to unauthorized access, allowing hackers to bypass the controls in place. A backdoor gives cybercriminals a way to sneak in and steal personally identifiable information (PII) and protected healthcare information (PHI). So, how big a threat are backdoors? The Backdoor Threat Level: FDA Issues Risk Alert At the end of January 2025, the FDA issued a specific risk alert related to backdoors, calling out two patient safety monitors. The agency identified these vulnerabilities: • An unauthorized user could remotely control the patient monitoring system. They would be able to perform unwanted actions or crash the device completely. • The software within the devices has a backdoor, which would compromise the device and network if connected. • After the device connects to the internet, it begins to collect patient data (PII and PHI) and exfiltrate information from outside the healthcare delivery environment. The FDA stated it had not received any reports relating to incidents or patient safety because of the vulnerabilities. The FDA and the Cybersecurity and Infrastructure Security Agency (CISA) are currently working with the manufacturer to resolve the issue. The alert also relayed that the FDA had authorized these monitors for wired functionality only. However, the agency was aware that some users were connecting via Wi-Fi. The cyberattack method in the backdoor only becomes active after joining networks and the IP address connected to it does not belong to the manufacturer or a healthcare organization. Instead, it was the property of a university. The tip for this came from an external researcher via the coordinated vulnerability disclosure process, and CISA then tested the theory, finding it to be true. A backdoor isn't always malicious. Sometimes, manufacturers enable this to make updates. Manufacturers are required to have updating and patching protocols once devices are on the market. That was not the case with these patient monitoring systems. Checks And Balances For Backdoors How did this backdoor gain the power to overwrite files on the device? The FDA's current guidelines have requirements that pertain to backdoors in place. The first is the software bill of materials (SBOM). Manufacturers must submit these with their application to the FDA for approval. An SBOM lists all pieces of software within a device and its dependencies and metadata. It's an 'inventory' to ensure transparency and mitigate risk. The motivation behind mandating SBOMs is to identify all code, most of which is open source, and ensure that what's in use is the most up to date. Older versions of much open code have vulnerabilities. In fact, an open-source security report concluded that 86% of codebases assessed had vulnerabilities and 81% had high levels of risk. Those percentages have risen considerably from years past. An SBOM should act as a transparency mechanism and allow for proper tracking of code so that if anyone finds a vulnerability, it should lead to earlier detection and remedy. These devices have been on the market for some time. Even before SBOMs were mandatory, most premarket submissions included them, but they weren't seriously scrutinized. A Deeper Dive Into The Code In the technical document from CISA researchers, key insights emerged on why the device's software was flagged. The code didn't have any of the features that are best practices for updating. The devices must have a way to update with patches, but this backdoor lacked standard security postures. For example, there was no integrity verification or way to record overwritten files. The other big tell was that remote file sharing was via an IP address, not a DNS entry. How The Backdoor Got Through In the technical breakdown and alert, the FDA does not provide any information on this. The company also hasn't issued a response, according to media outlets reporting the story. Additionally, no software patch is currently available. The recommendation from experts is simply to disconnect the devices. The consequence of this could impact patient care since these patient monitoring devices are in heavy use. Since the alert came from an outside researcher, it also points to the question of risk assessment by organizations using it. Potentially, penetration testing, vulnerability scanning or other proactive cybersecurity measures would have also found the backdoor. There is no easy answer to curbing the cyber threats to medical devices. They have become integral in patient care, but manufacturers and providers should be continuously evaluating threats and vulnerabilities. As devices come onto the market that have to follow the new FDA guidance of SBOMs and patching, backdoors may become easier to prevent and detect. For the entire industry, this is a stark reminder that threats can easily disguise themselves. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Yahoo
4 days ago
- Business
- Yahoo
Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US
Johnson & Johnson (NYSE:JNJ) is one of the 10 Best and Cheap Stocks to Buy Now. On June 19, Johnson & Johnson (NYSE:JNJ) announced the launch of two new plating systems in the United States under its VOLT platform, called Distal Radius and Proximal Humerus 3.5 Plating Systems. The systems are designed to treat the two most commonly fractured bones, which are the distal radius near the wrist and the proximal humerus near the shoulder. These injuries are common in people above 65 years old. Johnson & Johnson (NYSE:JNJ) designed these systems in collaboration with the Hand Expert Group from the AO Technical Commission. The new plate has a new shape that sits more distally on the bone fragments and has a less prominent profile to reduce soft tissue irritation, thereby improving the overall comfort and healing process. A smiling baby with an array of baby care products in the foreground. Johnson & Johnson (NYSE:JNJ) highlighted that the systems fill in a critical gap in the current treatment of fractures. The systems are now readily available across the United States. Johnson & Johnson (NYSE:JNJ) is an international global healthcare company. The company operates through two segments including innovative medicine and MedTech. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
